Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00277
|
|||||
| Drug Name |
Ipratropium
|
|||||
| Synonyms |
(+-)-Ipratropine; (3-endo,8-syn)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane; (3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-isopropyl-8-methyl-8-azoniabicyclo[3.2.1]octane; (8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate; 3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-(propan-2-yl)-8-azoniabicyclo[3.2.1]octane; Aerodose; Aerovent; Apo-Ipravent; Apovent; Apovent (TN); Atronase; Atrovent; Atrovent (TN); Atrovent Aerosol; Atrovent Hfa; Atrovent Nasal; Bitrop; Disne-Asmol; Ipatropium Bromide; Ipratropium bromide; Ipravent; Ipvent; Kendral-Ipratropium; N-Isopropylatropine; Narilet; Rhinotrop; Rhinovent; Rinatec; Rinoberen; Rinovagos; Vagos; X8M; [(1R,5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] (2R)-3-hydroxy-2-phenylpropanoate; [(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Obstructive lung diseases [ICD11:CA22.Z] | Approved | [1] | |||
| Therapeutic Class |
Bronchodilator Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C20H30NO3+
|
|||||
| Canonical SMILES |
CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C
|
|||||
| InChI |
InChI=1S/C20H30NO3/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15/h4-8,14,16-19,22H,9-13H2,1-3H3/q+1
|
|||||
| InChIKey |
OEXHQOGQTVQTAT-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 60205-81-4
|
|||||
| Pharmaceutical Properties | Molecular Weight | 332.5 | Topological Polar Surface Area | 46.5 | ||
| Heavy Atom Count | 24 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 3 | |||
| XLogP |
2.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103127404
,104170067
,104304400
,11466603
,11467723
,11486345
,117575154
,121362439
,124886805
,124968912
,126407694
,128799107
,135650410
,136350344
,136959634
,140035998
,141999271
,142186678
,142719345
,160857166
,162879438
,166233201
,172080692
,176484704
,179148622
,179694577
,226395381
,237172531
,239293942
,242128594
,244502426
,246151890
,248499359
,26756583
,29222866
,47509536
,50070857
,5243543
,5243557
,6951281
,79331559
,8152369
,85209499
,85788108
|
|||||
| ChEBI ID |
ChEBI:5956
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | 1-Oct | Transporter Info | Organic cation transporter 1 | Substrate | [2] | |
| OCTN1 | Transporter Info | Organic cation/carnitine transporter 1 | Substrate | [3] | ||
| OCTN2 | Transporter Info | Organic cation/carnitine transporter 2 | Substrate | [3] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | 1-Oct | Transporter Info | Km =9 microM | Human embryonic kidney cells (HEK293)-OCT1 | [2] | |
| OCTN1 | Transporter Info | Km =444 microM | Human embryonic kidney cells (HEK293)-OCTN1 | [3] | ||
| OCTN2 | Transporter Info | Km =53 microM | Human embryonic kidney cells (HEK293)-OCTN2 | [3] | ||
| References | ||||||
| 1 | Ipratropium was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42. | |||||
| 3 | Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.